"Bavarian Nordic Shifts Focus to Infectious Diseases, Abandons Cancer Vaccine Development"

Bavarian Nordic has decided to shift its focus from immuno-oncology vaccine development to infectious disease research and development, discontinuing its Phase I cancer vaccine program in favor of concentrating on its mpox vaccine Jynneos, which is expected to contribute to the company's strong 2023 sales. The Danish biotech's TAEK-VAC, a cancer vaccine targeting a tumor-associated antigen, was being studied in patients with chordoma or HER2-positive breast cancer.